These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36535950)

  • 21. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
    Gopal S; Xu H; Bossie C; Burón JA; Fu DJ; Savitz A; Nuamah I; Hough D
    Int J Clin Pract; 2014 Dec; 68(12):1514-22. PubMed ID: 25358867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
    Carter NJ
    Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
    J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia: An Open-Label Extension Study of a Randomized Clinical Trial.
    Correll CU; Johnston K; Turkoz I; Gray J; Sun L; Doring M; Sajatovic M
    JAMA Netw Open; 2024 Jul; 7(7):e2421495. PubMed ID: 39018073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.
    Anderson JP; Icten Z; Alas V; Benson C; Joshi K
    BMC Psychiatry; 2017 Oct; 17(1):346. PubMed ID: 29047368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics.
    Schreiner A; Lahaye M; Peuskens J; Naber D; Dilbaz N; Millet B; Franco MA; Rancans E; Turczynski J; Smeraldi E; Lara E; Neznanov NG
    Expert Opin Pharmacother; 2014 Apr; 15(5):593-603. PubMed ID: 24491033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paliperidone extended-release tablets: a new atypical antipsychotic.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 May; 45(5):15-8. PubMed ID: 17526326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paliperidone extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.
    Wang D; Wei N; Hu F; Li J; Wang Y; Qian Z; Yang M; Yao M; Xia Y; Yu H; Tu W; Ye M; Qian C; Hu J; Chen J; Hu C; Huang M; Xu Y; Hu S
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):383-390. PubMed ID: 35695720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
    Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
    Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
    Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia.
    Rui Q; Wang Y; Liang S; Liu Y; Wu Y; Wu Q; Nuamah I; Gopal S
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug; 53():45-53. PubMed ID: 24576532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.